FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

vvaoriirigiori,	D.O. 200 10	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Abdun-Nabi Daniel					2. Issuer Name <b>and</b> Ticker or Trading Symbol Aptevo Therapeutics Inc. [ APVO ]									all applic	cable) r	g Pers	son(s) to Iss	ner	
(Last) (First) (Middle) C/O APTEVO THERAPEUTICS INC.					3. Date of Earliest Transaction (Month/Day/Year) 07/02/2020										below)	(give title		Other (s below)	pecity
2401 4TH AVENUE, SUITE 1050					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)	E W	A !	98121											Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City)	(Si	ate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution Date,		3. Transaction Code (Instr. 8) 1			4 and Securitie Benefici Owned I		es ally following	Form (D) or	orm: Direct 0) or Indirect 1 (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) o (D)	r Price		Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date, Transac					Expiration D	Date Exercisable and piration Date onth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		De Se (In:	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiali Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	Code		(A)	(D)	Date Exercisable		piration te	Title	Amoun or Numbe of Shares						
Stock Option (right to buy)	\$9.18	07/02/2020			Α		3,571		(1)	07/	/02/2030	Common Stock	3,571		\$0	3,571		D	

## **Explanation of Responses:**

 $1. \ The \ option \ vests \ in \ three \ approximately \ equal \ annual \ installments \ beginning \ on \ July \ 2, \ 2021.$ 

/s/ Carl A. Valenstein, attorney-02/17/2021 in-fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).